SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Evolution of drug regulations and regulatory innovation for anticancer drugs in China
5 references·2 citing·26 second hop
Evolution of drug regulations and regulatory innovation for anticancer drugs in China (2022)Evolution of drug regulations and regulat…A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions (2021)A Decade of FDA-Approved Drug…Dynamics of life expectancy and life span equality (2020)Dynamics of life expectancy a…Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada (2018)Incorporating the patient exp…The changing landscape of clinical trial and approval processes in China (2017)The changing landscape of cli…Rare diseases, orphan drugs and their regulation: questions and misconceptions (2010)Rare diseases, orphan drugs a…Impact of China’s drug innovation policy on patent quantity and quality: Evidence from a representative chemical pharmaceutical enterprise (2025)Impact of China’s drug innova…Current landscape of innovative drug development and regulatory support in China (2025)Current landscape of innovati…How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Estimating the budget impact of orphan medicines in Europe: 2010 - 2020 (2011)Orphan drug development: an economically viable strategy for biopharma R&D (2012)Orphan drugs: the regulatory environment (2012)Linking Clinical Variables With Health-Related Quality of Life (1995)Linking Clinical Variables With Health-Related Quality of Life (1995)Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols (2018)Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes (2019)SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials (2021)Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types (2023)Distribution of the Estimators for Autoregressive Time Series With a Unit Root (1979)Testing the null hypothesis of stationarity against the alternative of a unit root (1992)Ageing populations: the challenges ahead (2009)Demographic perspectives on the mortality of COVID-19 and other epidemics (2020)Demographic perspectives on the rise of longevity (2021)Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries (2021)Diagnosing the decline in pharmaceutical R&D efficiency (2012)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019 (2022)The pharmaceutical productivity gap – Incremental decline in R&D efficiency despite transient improvements (2024)An overview of FDA-approved new molecular entities: 1827–2013 (2014)Trends in the approval of cancer therapies by the FDA in the twenty-first century (2023)The Economic Costs of Conflict: A Case Study of the Basque Country (2003)Innovation and firm growth: Does firm age play a role? (2015)Patent Quality: Towards a Systematic Framework for Analysis and Measurement (2021)Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020 (2022)
this work references cited by second hop

References

  • 2021A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions323 cited
  • 2020Dynamics of life expectancy and life span equality273 cited
  • 2018Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada199 cited
  • 2010Rare diseases, orphan drugs and their regulation: questions and misconceptions182 cited
  • 2017The changing landscape of clinical trial and approval processes in China68 cited

Cited by

  • 2025Current landscape of innovative drug development and regulatory support in China52 cited
  • 2025Impact of China’s drug innovation policy on patent quantity and quality: Evidence from a representative chemical pharmaceutical enterprise4 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work